Targeted Agents in AML (ABT199)

被引：0
|
作者：
Konopleva, Marina [1 ]
DiNardo, Courtney [1 ]
Pan, Rongqing Aaron [1 ]
Han, Lina [1 ]
Zhang, Qi [1 ]
Daver, Naval [1 ]
Kantarjian, Hagop [1 ]
Andreeff, Michael [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd 10, Houston, TX 77030 USA
来源：
ANNALS OF HEMATOLOGY | 2017年 / 96卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S28 / S29
页数：2
相关论文
共 50 条
  • [31] Targeting non-cycling acute myeloid leukaemia cells with ABT-737 and ABT-199
    Yu, N.
    Seedhouse, C.
    Russell, N.
    Pallis, M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 : 60 - 60
  • [32] ABT-199: Taking Dead Aim at BCL-2
    Davids, Matthew S.
    Letai, Anthony
    CANCER CELL, 2013, 23 (02) : 139 - 141
  • [33] Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax
    Ackler, Scott
    Oleksijew, Anatol
    Chen, Jun
    Chyla, Brenda J.
    Clarin, Jerry
    Foster, Kelly
    McGonigal, Thomas
    Mishra, Sasmita
    Schlessinger, Sally
    Smith, Morey L.
    Tahir, Stephen K.
    Leverson, Joel D.
    Souers, Andrew J.
    Boghaert, Erwin R.
    Hickson, Jonathan
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2015, 3 (05):
  • [34] Activity of ABT-199 and Acquired Resistance in Follicular Lymphoma Cells
    Bodo, Juraj
    Zhao, Xiaoxian
    Smith, Mitchell R.
    Hsi, Eric D.
    BLOOD, 2014, 124 (21)
  • [35] Mechanisms of resistance to ABT-199 in leukemia and lymphoma cell lines
    Tahir, Stephen K.
    Smith, Morey L.
    Hessler, Paul
    Roberts-Rapp, Lisa
    Leverson, Joel D.
    Lam, Lloyd T.
    CLINICAL CANCER RESEARCH, 2015, 21
  • [36] INTRINSIC AND SYNERGISTIC ACTIVITY OF ABT-199 AND OVERCOMING ABT-199 RESISTANCE BY THE CDK-INHIBITOR DINACICLIB IN B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
    Seyfried, F.
    Demir, S.
    Hoerl, R.
    Scheffold, A.
    Koehrer, S.
    Stilgenbauer, S.
    Debatin, K. M.
    Meyer, L. H.
    HAEMATOLOGICA, 2016, 101 : 29 - 29
  • [37] Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells
    Niu, Xiaojia
    Zhao, Jianyun
    Ma, Jun
    Xie, Chengzhi
    Edwards, Holly
    Wang, Guan
    Caldwell, J. Timothy
    Xiang, Shengyan
    Zhang, Xiaohong
    Chu, Roland
    Wang, Zhihong J.
    Lin, Hai
    Taub, Jeffrey W.
    Ge, Yubin
    CLINICAL CANCER RESEARCH, 2016, 22 (17) : 4440 - 4451
  • [38] Allosteric modulation of sigma receptors by BH3 mimetics ABT-737, ABT-263 (Navitoclax) and ABT-199 (Venetoclax)
    Lever, John R.
    Fergason-Cantrell, Emily A.
    PHARMACOLOGICAL RESEARCH, 2019, 142 : 87 - 100
  • [39] The Splenic Microenvironment Is a Novel Site of Relapse Following ABT-199 Treatment
    Di Grande, Alessandra
    Piers, Sofie
    Van Vlierberghe, Pieter
    Chonghaile, Triona Ni
    BLOOD, 2019, 134
  • [40] The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
    C Touzeau
    C Dousset
    S Le Gouill
    D Sampath
    J D Leverson
    A J Souers
    S Maïga
    M C Béné
    P Moreau
    C Pellat-Deceunynck
    M Amiot
    Leukemia, 2014, 28 : 210 - 212
12345